Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL

Sponsor

Gilead Sciences (Industry)

Overall Status

Terminated

CT.gov ID

NCT01585688

Collaborator

(none)

Enrollment

Locations

Arm

Actual Duration (Months)

2.2

Patients Per Site

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The primary objectives are to evaluate the safety and tolerability of hLL1-DOX, and to determine the maximum tolerated dose (MTD) regimen (in terms of a dose and its associated dosing schedule). The secondary objectives are to obtain information on efficacy, pharmacodynamics, pharmacokinetics, and immunogenicity, and to determine the optimal dose for subsequent studies.

Condition or Disease	Intervention/Treatment	Phase
Non-Hodgkin's Lymphoma Chronic Lymphocytic Leukemia	Drug: hLL1-DOX (IMMU-115)	Phase 1/Phase 2

Detailed Description

Patients receive hLL1-DOX at one of 4 dose levels administered on Days 1, 4, 8 and 11 of 21-day treatment cycles which are continued in the absence of progression or unacceptable toxicity up to a total of 8 cycles. After treatment, follow-up will be done at 4, 8 and 12 weeks post-treatment and will continue to be done every 3 months for up to 2 years.

Study Design

Study Type:

Interventional

Actual Enrollment :

13 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase I/II Study of Immunotherapy With hLL1-DOX in Patients With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Actual Study Start Date :

Aug 1, 2012

Actual Primary Completion Date :

Nov 1, 2016

Actual Study Completion Date :

Oct 1, 2017

Arms and Interventions

Arm	Intervention/Treatment
Experimental: hLL1-DOX	Drug: hLL1-DOX (IMMU-115) hLL1-DOX is administered intravenously at one of 4 dose levels on days 1, 4, 8 and 11 of 21-day treatment cycles, with up to 8 cycles administered. Other Names: IMMU-115

Arm

Intervention/Treatment

Experimental: hLL1-DOX

Drug: hLL1-DOX (IMMU-115)

hLL1-DOX is administered intravenously at one of 4 dose levels on days 1, 4, 8 and 11 of 21-day treatment cycles, with up to 8 cycles administered.

Other Names:

IMMU-115

Outcome Measures

Primary Outcome Measures

Evaluate the safety and tolerability of hLL1-DOX [These assessments will be done routinely during treatment & changes at 4, 8 & 12 weeks after treatment]
NCI CTCAE version 4.0 is used to grade all adverse events
All patients who were treated and meet the efficacy criteria for response assessment will be included in the analysis of efficacy [During treatment and the changes at 4, 8 and 12 weeks after treatment and then every 3 months for up to 2 years]
For the primary efficacy evaluations, the proportion of responders (defined as patients with a best response of PR or CR) will be tabulated for each dose level. In addition, the progression-free survival (PFS, as measured from start of treatment to disease progression, death or last follow-up) will be summarized using Kaplan-Meier survival analysis methods. Similarly, for responders at each dose level, the duration of response (DR, as measured from time of first response to relapse or last follow-up) will also be summarized using Kaplan- Meier survival analysis methods, if appropriate.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Male or female, age ≥ 18 years
Able to provide signed, informed consent
Histologically confirmed diagnosis of recurrent B-cell non-Hodgkin's lymphoma (any histology by WHO criteria) or recurrent chronic lymphocytic leukemia (by NCI criteria) (Reference Appendix C)
Received at least one prior treatment with standard therapy (previous antibody therapy is acceptable)
Measurable disease at least one lesion ≥ 1.5 cm for NHL and ALC > 5,000 for CLL
Adequate performance status (≥ 70 Karnofsky scale) with an estimated life expectancy of at least 6 months

--Documented negative hepatitis B screen, per NCCN guidelines (hepatitis B surface antigen/antibodies, core antigen/antibodies, hepatitis B e-antigen)

At least 12 weeks beyond stem cell transplant and 4 weeks beyond chemotherapy or immunotherapy, major surgery, other experimental treatments, or radiation therapy to the index lesions, and with all acute toxicities from prior therapy resolved to less than Grade 2 toxicity by NCI CTC version 4.0
Laboratory parameters:

Adequate hematology without ongoing transfusional support Hemoglobin >/= 10 g/dL Absolute neutrophil count >/= 1.5 x 10 9/L Platelets >/= 75 x 10 9/L Creatinine and bilirubin </= 1.5 x IULN AST and ALT </= 2.5 x IULN

-Adequate cardiac function (MUGA scan or 2-D ECHO with LVEF ≥ 55%, EKG with no medically relevant arrhythmia uncontrolled on medications)

Exclusion Criteria:

-Pregnant or lactating women. Women of childbearing potential must have a negative pregnancy test. Pregnancy testing is not required for post-menopausal or surgically sterilized women.
Women of childbearing potential and fertile men who are not practicing or who are unwilling to practice birth control while enrolled in the study until at least 12 weeks after the last milatuzumab infusion
Prior therapy with other human or humanized monoclonal antibodies, unless HAHA tested and negative
Prior treatment with trastuzumab
Bulky disease by CT, defined as any single mass > 10 cm in its greatest diameter
Known HIV positive or active hepatitis B or C, or presence of hepatitis B surface antigens or presence of hepatitis C antibody
New York Heart Classification III or IV heart disease (see Appendix G). Other severe cardiovascular or cardiopulmonary disease, including COPD
Baseline BNP > 2 x IULN
Patients with uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities will be excluded
Patients with recent (≤ 6 months) cardiac angina, difficult to control congestive heart failure, uncontrolled hypertension, or difficult to control cardiac arrhythmias will be excluded
Known autoimmune disease or presence of autoimmune phenomena
At least 7 days beyond any infection requiring intravenous antibiotic use (Oral antibiotics may be administered prophylactically as clinically indicated)
Systemic corticosteroids within 2 weeks, except low dose regimens (prednisone, ≤ 20 mg/day, or equivalent) which may continue if unchanged
Substance abuse or other concurrent medical or psychiatric conditions that, in the Investigator's opinion, could confound study interpretation or affect the patient's ability to tolerate or complete the study

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Helen F. Graham Cancer Center	Newark	Delaware	United States	19713
2	MD Anderson Cancer Center Orlando	Orlando	Florida	United States	32806
3	IU Health Goshen Center for Cancer Care	Goshen	Indiana	United States	46526
4	UMass Memorial Cancer Center of Excellence	Worcester	Massachusetts	United States	01605
5	John Theurer Cancer Center Hackensack University Medical Center	Hackensack	New Jersey	United States	07601
6	U.T. MD Anderson Cancer Center Houston	Houston	Texas	United States	77030